Market Overview

UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership Discussion

Related AMRN
Stocks to Watch for October 23, 2014
Week Concludes With S&P 500 Below 2,000; Dow Below 17,000

In a report published Friday, Jefferies analyst Thomas Wei reiterated a Buy rating on Amarin (NASDAQ: AMRN), but lowered the price target from $24.00 to $20.00.

In the report, Jefferies noted, “We remain focused on the FDA panel meeting in October for ANCHOR and the launch of ANCHOR in 1H14 as the key catalysts for AMRN shares. The company remains in negotiations for a pharma partnership for ANCHOR, but also discussed the merits of self-commercialization.”

Amarin closed on Thursday at $5.31.

Latest Ratings for AMRN

DateFirmActionFromTo
Nov 2014CitigroupMaintainsNeutral
May 2014CitigroupDowngradesBuyNeutral
Feb 2014Aegis CapitalMaintainsHold

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Jefferies Thomas WeiAnalyst Color Price Target Analyst Ratings

 

Related Articles (AMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters